PDGFRA and gastrointestinal stromal tumor: The remaining 10-15% of GISTs do not harbor identified receptor tyrosine-kinase mutations (KIT/PDGFRα wild-type GIST) and are very different from mutant GISTs in their clinical and molecular profiles, to the extent that they are now considered a separate pathological entity with wide heterogeneity [1, 2].